All Resources

April 28, 2022

Reflections on a Potential Pan-Canadian Drug Formulary: Medicines Industry Response to CADTH Consultation

Learn more|View

Access to Medicine • February 12, 2022

Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing

Learn more|View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more|View

Drugs for Rare Diseases (DRD) • September 15, 2021

Addendum to IMC Submission on Drugs for Rare Diseases

Learn more|View

Drugs for Rare Diseases (DRD) • March 26, 2021

Towards a Value-based and Pan-Canadian Rare Disease Strategy

Learn more|View

Access to Medicine • August 20, 2020

IMC and BTC joint response to CADTH’s transparency consultation

IMC and and BIOTECanada write to Suzanne McGurn with joint input on the current CADTH process consultation….

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • August 04, 2020

IMC Response to PMPRB 2020 Draft Guidelines

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • February 14, 2020

IMC Response to PMPRB Draft Guidelines

Learn more|View

January 30, 2020

2019 Annual Report

Learn more|View

Access to Medicine • April 28, 2019

pCPA Brand Practice Guidelines

Learn more|View

March 29, 2019

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans (March 2019)

Learn more|View

February 18, 2019

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications (February 2019)

Learn more|View